PeptidePedia The community reference

Talk:Timeline of incretin therapeutics

Discussion page·2 threads·no archives

This article is within the scope of the clinical evidence working group.

This is the discussion page for the article Timeline of incretin therapeutics. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

The 1986 hingeResolved

Calling the reduced-incretin-effect finding the hinge of the field is a judgement, but a defensible one — it converts physiology into a target. — TimelineTiernan (talk) 09:45, 11 February 2026 (UTC)

And the reasoning is given, so a reader can disagree with it. ✓ Done — IncretinIvo (talk) 13:20, 11 February 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Approval dates are jurisdictionalDone

Stating that dates are first approval in a major market avoids the timeline being read as global. — LabelLibby (talk) 10:15, 31 May 2026 (UTC)

Noted in the lead with a pointer to the status article. ✓ Done — TimelineTiernan (talk) 13:50, 31 May 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.
This page was last edited on 31 May 2026, by TimelineTiernan. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).